Newron Pharmaceuticals SpA - Strategy, SWOT and Corporate Finance Report

Newron Pharmaceuticals SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Newron Pharmaceuticals SpA (Newron) is a research-based biopharmaceutical company which focuses on the discovery, development and commercialization of novel therapeutic drugs for the treatment of central nervous system disorders and pain. The company’s marketed product, Xadago (safinamide), is developed as an adjunctive therapy for any stage of Parkinson's disease. Newron’s other products in pipeline include ralfinamide for neuropathic pain; sarizotan for Rett syndrome; and Evenamide (NW-3509) for the treatment of schizophrenia. The company has development and commercialization collaborations with Zambon and Meiji Seika Pharma Co., Ltd. It operates along with its subsidiaries in the UK, Sweden, Switzerland and the US. Newron is headquartered in Bresso, Milan, Italy.

Scope

  • Detailed information on Newron Pharmaceuticals SpA required for business and competitor intelligence needs
  • A study of the major internal and external factors affecting Newron Pharmaceuticals SpA in the form of a SWOT analysis
  • An in-depth view of the business model of Newron Pharmaceuticals SpA including a breakdown and examination of key business segments
  • News about Newron Pharmaceuticals SpA, such as business expansion, restructuring, and contract wins
  • Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

  • Gain understanding of Newron Pharmaceuticals SpA and the factors that influence its strategies.
  • Track strategic initiatives of the company and latest corporate news and actions.
  • Assess Newron Pharmaceuticals SpA as a prospective partner, vendor or supplier.
  • Support sales activities by understanding your customers' businesses better.
  • Stay up to date on Newron Pharmaceuticals SpAs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Ablynx NV

Biotie Therapies Corp

Pharming Group NV

Santhera Pharmaceuticals Holding AG

Silence Therapeutics Plc

Ablynx NV

Biotie Therapies Corp

Pharming Group NV

Santhera Pharmaceuticals Holding AG

Silence Therapeutics Plc

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1 - About the Company 6

Newron Pharmaceuticals SpA ...

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1 - About the Company 6

Newron Pharmaceuticals SpA - Key Facts 6

Newron Pharmaceuticals SpA - Key Employees 7

Newron Pharmaceuticals SpA - Key Employee Biographies 8

Newron Pharmaceuticals SpA - Major Products and Services 9

Newron Pharmaceuticals SpA - History 10

Newron Pharmaceuticals SpA - Company Statement 13

Newron Pharmaceuticals SpA - Locations And Subsidiaries 15

Head Office 15

Other Locations & Subsidiaries 15

Section 2 – Company Analysis 16

Company Overview 16

Newron Pharmaceuticals SpA - Business Description 16

Newron Pharmaceuticals SpA - Corporate Strategy 17

Newron Pharmaceuticals SpA - SWOT Analysis 18

SWOT Analysis - Overview 18

Newron Pharmaceuticals SpA - Strengths 18

Newron Pharmaceuticals SpA - Weaknesses 19

Newron Pharmaceuticals SpA - Opportunities 20

Newron Pharmaceuticals SpA - Threats 21

Newron Pharmaceuticals SpA - Key Competitors 22

Section 3 – Company Financial Ratios 23

Financial Ratios - Capital Market Ratios 23

Financial Ratios - Annual Ratios 24

Performance Chart 26

Financial Performance 26

Financial Ratios - Interim Ratios 27

Financial Ratios - Ratio Charts 28

Section 4 – Company’s Lifesciences Financial Deals and Alliances 29

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30

Newron Pharmaceuticals SpA, Recent Deals Summary 31

Section 5 – Company’s Recent Developments 32

Mar 27, 2018: Newron Pharmaceuticals Announces Shareholders Accepted All Motions at the AGM 2018 32

Mar 01, 2018: Newron Announces 2017 Financial Results and Provides Outlook for 2018 33

Feb 13, 2018: Newron Supports Global Rare Disease Day 2018 and Rett Syndrome Studies 36

Dec 11, 2017: Newron Provides End of Year Corporate Update 37

Nov 07, 2017: Newron Pharmaceuticals Announces Advisory Board Recommendations and Rett Congress Findings 38

Sep 14, 2017: Newron reports half-year 2017 results 39

May 18, 2017: Newron Announces a Poster Presentation at the International Society for Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting 41

Apr 05, 2017: Eisai and Meiji to commercialise safinamide for Parkinson’s disease in Japan and Asia 42

Apr 05, 2017: Eisai and Meiji to commercialise safinamide for Parkinson’s disease in Japan and Asia 43

Mar 02, 2017: Newron announces 2016 financial results and provides outlook for 2017 44

Section 6 – Appendix 45

Methodology 45

Ratio Definitions 45

About GlobalData 49

Contact Us 49

Disclaimer 49

List of Tables

List of Tables

Newron Pharmaceuticals SpA, Key Facts 6

Newron Pharmaceuticals SpA, Key Employees 7

Newron Pharmaceuticals SpA, Key Employee Biographies 8

Newron Pharmaceuticals SpA, ...

List of Tables

Newron Pharmaceuticals SpA, Key Facts 6

Newron Pharmaceuticals SpA, Key Employees 7

Newron Pharmaceuticals SpA, Key Employee Biographies 8

Newron Pharmaceuticals SpA, Major Products and Services 9

Newron Pharmaceuticals SpA, History 10

Newron Pharmaceuticals SpA, Subsidiaries 15

Newron Pharmaceuticals SpA, Key Competitors 22

Newron Pharmaceuticals SpA, Ratios based on current share price 23

Newron Pharmaceuticals SpA, Annual Ratios 24

Newron Pharmaceuticals SpA, Annual Ratios (Cont...1) 25

Newron Pharmaceuticals SpA, Interim Ratios 27

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30

Newron Pharmaceuticals SpA, Recent Deals Summary 31

Currency Codes 45

Capital Market Ratios 45

Equity Ratios 46

Profitability Ratios 46

Cost Ratios 47

Liquidity Ratios 47

Leverage Ratios 48

Efficiency Ratios 48

List of Figures

List of Figures

Newron Pharmaceuticals SpA, Performance Chart (2013 - 2017) 26

Newron Pharmaceuticals SpA, Ratio Charts 28

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals ...

List of Figures

Newron Pharmaceuticals SpA, Performance Chart (2013 - 2017) 26

Newron Pharmaceuticals SpA, Ratio Charts 28

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 30

    Pricing

Discounts available for multiple report purchases.

reportstore@marketline.com
+44 (0) 161 359 5817

Saved reports